This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Snydman, D. R.
Right arrow Articles by McDermott, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Snydman, D. R.
Right arrow Articles by McDermott, L. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2008, p. 4492-4496, Vol. 52, No. 12
0066-4804/08/$08.00+0     doi:10.1128/AAC.00696-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Doripenem, a New Broad-Spectrum Carbapenem, against Recently Collected Clinical Anaerobic Isolates, with Emphasis on the Bacteroides fragilis Group {triangledown}

David R. Snydman,1,2* Nilda V. Jacobus,1 and Laura A. McDermott1

Tufts Medical Center,1 Tufts University Medical School, Boston, Massachusetts2

Received 28 May 2008/ Returned for modification 20 August 2008/ Accepted 27 September 2008

Doripenem was evaluated against 527 recent clinical isolates, i.e., 404 Bacteroides fragilis isolates and 123 gram-positive anaerobe isolates. Against B. fragilis, doripenem was as active as imipenem, meropenem, and piperacillin-tazobactam and more active than ertapenem or ampicillin-sulbactam. Doripenem was active against isolates resistant to ertapenem, ampicillin-sulbactam, cefoxitin, clindamycin, and moxifloxacin. All of the gram-positive isolates tested were susceptible to doripenem.

* Corresponding author. Mailing address: Division of Geographic Medicine and Infectious Diseases, Box 238, Tufts-New England Medical Center, 750 Washington Street, Boston, MA 02111. Phone and fax: (617) 636-8525. E-mail: DSnydman{at}tuftsmedicalcenter.org

{triangledown} Published ahead of print on 6 October 2008.

Antimicrobial Agents and Chemotherapy, December 2008, p. 4492-4496, Vol. 52, No. 12
0066-4804/08/$08.00+0     doi:10.1128/AAC.00696-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Shea, K. M, Cheatham, S C., Smith, D. W, Wack, M. F, Sowinski, K. M, Kays, M. B (2009). Comparative Pharmacodynamics of Intermittent and Prolonged Infusions of Piperacillin/Tazobactam Using Monte Carlo Simulations and Steady-State Pharmacokinetic Data from Hospitalized Patients. The Annals of Pharmacotherapy 43: 1747-1754 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»